Advertisement

Drugs

, Volume 74, Issue 16, pp 1961–1971 | Cite as

Eltrombopag: A Review of Its Use in the Treatment of Thrombocytopenia in Patients with Chronic Hepatitis C

  • Celeste B. Burness
Adis Drug Evaluation

Abstract

Eltrombopag (Revolade®; Promacta®) is an orally bioavailable, small-molecule, thrombopoietin receptor agonist that selectively binds to thrombopoietin receptors on megakaryocyte precursors and megakaryocytes leading to increased platelet production. It is approved in a number of countries for the treatment of thrombocytopenia, including adult patients with chronic hepatitis C virus (HCV) infection to allow for the initiation and maintenance of peginterferon-based therapy, which is the focus of this review. In two, well-designed, randomized controlled trials in adults with chronic HCV infection and thrombocytopenia (ENABLE-1 and ENABLE-2), eltrombopag increased platelet counts to sufficient levels to allow for the initiation of peginterferon-based antiviral therapy in 95 % of patients whose baseline platelet counts would have made them ineligible or marginal candidates for peginterferon therapy. Moreover, a significantly higher proportion of eltrombopag recipients than placebo recipients achieved a sustained virological response (primary endpoint) 24 weeks after the completion of antiviral therapy. Of note, the additional benefit over placebo was relatively small (<10 %). Compared with placebo, eltrombopag was associated with fewer patients discontinuing antiviral therapy early and a numerically greater proportion of patients not requiring antiviral dose reduction. Oral eltrombopag had an acceptable tolerability profile; however, there is an increased risk of adverse events, including potentially fatal hepatic decompensation and thromboembolic events. Eltrombopag provides a new treatment option for thrombocytopenia in patients with chronic HCV infection to allow for optimal antiviral therapy.

Keywords

Sustained Virologic Response Sustained Virologic Response Rate Eltrombopag Hepatic Decompensation Breast Cancer Resistance Protein Substrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. Celeste B. Burness is a salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–32.CrossRefGoogle Scholar
  2. 2.
    World Health Organization. Guideline for the screening, care and treatment of persons with hepatitis infection. 2014. http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1. Accessed 12 Sept 2014.
  3. 3.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–82.CrossRefGoogle Scholar
  4. 4.
    American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2014. http://www.hcvguidelines.org/. Accessed 10 Aug 2014.
  5. 5.
    Fouad YM. Chronic hepatitis C-associated thrombocytopenia: aetiology and management. Trop Gastroenterol. 2013;34(2):58–67.CrossRefGoogle Scholar
  6. 6.
    Genentech Inc. PEGASYS (peginterferon alfa-2a): US prescribing information. 2013. http://www.gene.com/download/pdf/pegasys_prescribing.pdf. Accessed 15 Sept 2014.
  7. 7.
    Merck and CO. PEGINTRON® (peginterferon alfa-2b) injection, for subcutaneous use: US prescribing information. 2013. http://www.merck.com/product/usa/pi_circulars/p/pegintron/pegintron_pi.pdf. Accessed 15 Sept 2014.
  8. 8.
    Calvaruso V, Craxi A. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32(Suppl 1):2–8.CrossRefGoogle Scholar
  9. 9.
    Maan R, van der Meer AJ, Hansen BE, et al. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. J Hepatol. 2014;61(3):482–91.CrossRefGoogle Scholar
  10. 10.
    Danish FA, Koul SS, Subhani FR, et al. Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. Saudi J. 2010;16(1):51–6.Google Scholar
  11. 11.
    Afdhal NH, McHutchison JG. Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection. Aliment Pharmacol Ther. 2007;26(Suppl 1):29–39.CrossRefGoogle Scholar
  12. 12.
    GlaxoSmithKline. Revolade 25 mg film-coated tablets: summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001110/WC500089964.pdf. Accessed 15 Sept 2014.
  13. 13.
    GlaxoSmithKline. PROMACTA® (eltrombopag) tablets: US prescribing information. 2014. http://www.gsksource.com/gskprm/htdocs/documents/PROMACTA-PI-MG-COMBINED.PDF. Accessed 15 Sept 2014.
  14. 14.
    Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27(2):424–30.CrossRefGoogle Scholar
  15. 15.
    Garnock-Jones KP. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs. 2011;71(10):1333–53.CrossRefGoogle Scholar
  16. 16.
    Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs. 2009;69(5):567–76.CrossRefGoogle Scholar
  17. 17.
    McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227–36.CrossRefGoogle Scholar
  18. 18.
    Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014;146(2):442–52.CrossRefGoogle Scholar
  19. 19.
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) group of an extension of marketing authorisation and variations assessment report for Revolade (eltrombopag): procedure no. EMEA/H/C/001110/X/0012G. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001110/WC500152310.pdf. Accessed 15 Sept 2014.
  20. 20.
    Farrell C, Hayes SC, Wire M, et al. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. Br J Clin Pharmacol. 2014;77(3):532–44.CrossRefGoogle Scholar
  21. 21.
    Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109(11):4739–41.CrossRefGoogle Scholar
  22. 22.
    Shida Y, Takahashi N, Nohda S, et al. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol and Ther. 2011;42(1):11–20.CrossRefGoogle Scholar
  23. 23.
    Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–47.CrossRefGoogle Scholar
  24. 24.
    Erhardt JA, Erickson-Miller CL, Aivado M, et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009;37(9):1030–7.CrossRefGoogle Scholar
  25. 25.
    Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012;119(17):4066–72.CrossRefGoogle Scholar
  26. 26.
    Matthys G, Park JW, McGuire S, et al. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol. 2010;70(1):24–33.CrossRefGoogle Scholar
  27. 27.
    Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764–76.CrossRefGoogle Scholar
  28. 28.
    Deng Y, Madatian A, Wire MB, et al. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos. 2011;39(9):1734–46.CrossRefGoogle Scholar
  29. 29.
    Bauman JW, Vincent CT, Peng B, et al. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol. 2011;51(5):739–50.CrossRefGoogle Scholar
  30. 30.
    Wire MB, McLean HB, Pendry C, et al. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2012;56(6):2846–51.CrossRefGoogle Scholar
  31. 31.
    Jenkins J, Williams D, Deng Y, et al. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol. 2010;66(1):67–76.CrossRefGoogle Scholar
  32. 32.
    Allred AJ, Bowen CJ, Park JW, et al. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol. 2011;72(2):321–9.CrossRefGoogle Scholar
  33. 33.
    Afdhal N, Giannini EG, Sigal S, et al. Improved SVR in a unique cohort of non-cirrhotic thrombocytopenic patients with hepatitis C virus (HCV) treated in the global multicenter ENABLE 1 and 2 trials [abstract 1725]. Hepatology. 2012;56(Suppl 4):995A.Google Scholar
  34. 34.
    Berg T, Riordan S, Karamanolis D, et al. ENABLE-ALL: safety and efficacy of eltrombopag in thrombocytopenic hepatitis C virus-infected patients with cirrhosis who withdrew from the ENABLE-1&2 studies [abstract no. 140]. In: 23rd annual conference of APASL, Brisbane; 2014.Google Scholar
  35. 35.
    Chen PJ, Han KH, Dusheiko GM, et al. Eltrombopag as a supportive agent to enable antiviral therapy in east asian patients with thrombocytopenia and hepatitis C virus [abstract no. 1988 plus poster]. Hepatol Int. 2013;7(Suppl 1):S417–S8.Google Scholar
  36. 36.
    Merck. Rebetol® (ribavirin): US prescribing information. 2013. https://www.merck.com/product/usa/pi_circulars/r/rebetol/rebetol_pi.pdf. Accessed 15 Sept 2014.
  37. 37.
    Afdhal N, Giannini EG, Sigal S, et al. Albumin and MELD score predict decompensation in patients with HCV cirrhosis and thrombocytopenia on interferon therapy: analysis from the ENABLE studies [abstract 1138 plus poster]. Hepatology. 2012;56(Suppl 4):738A–9A.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations